付款人-患者参与框架,以加强美国罕见疾病领域的伦理处方决策

Siva Narayanan
{"title":"付款人-患者参与框架,以加强美国罕见疾病领域的伦理处方决策","authors":"Siva Narayanan","doi":"10.2217/frd-2022-0016","DOIUrl":null,"url":null,"abstract":"Aim: Develop a Payer–Patient Engagement Framework (PPEF) in rare disease (RD) to incorporate patient preferences/input into payer formulary decisions in the USA. Materials & methods: Targeted literature reviews related to drug value assessment, ethical decision-making and corporate social performance theories were conducted, and integrated with results from 24 payer and patient stakeholder interviews in the USA to construct PPEF. Results: Published literature revealed scant use of patient preferences/input by payers, and the potential relationship between payer's ethical formulary decisions and payer's moral intent/behavior/actions, and their external credibility and reputation. Payer/patient interviews identified formal and informal ways to solicit patient input and incorporate them in drug formulary review materials. PPEF was formulated to engage patients, assess, and act on evidence and perform transparent external communication. Conclusion: PPEF could enable payers to formally solicit and utilize patient input to strengthen RD formulary decisions and enhance orphan drug access and RD patient outcomes.","PeriodicalId":432772,"journal":{"name":"Future Rare Diseases","volume":"112 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Payer–patient engagement framework to strengthen ethical formulary decision-making in rare disease arena in the USA\",\"authors\":\"Siva Narayanan\",\"doi\":\"10.2217/frd-2022-0016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: Develop a Payer–Patient Engagement Framework (PPEF) in rare disease (RD) to incorporate patient preferences/input into payer formulary decisions in the USA. Materials & methods: Targeted literature reviews related to drug value assessment, ethical decision-making and corporate social performance theories were conducted, and integrated with results from 24 payer and patient stakeholder interviews in the USA to construct PPEF. Results: Published literature revealed scant use of patient preferences/input by payers, and the potential relationship between payer's ethical formulary decisions and payer's moral intent/behavior/actions, and their external credibility and reputation. Payer/patient interviews identified formal and informal ways to solicit patient input and incorporate them in drug formulary review materials. PPEF was formulated to engage patients, assess, and act on evidence and perform transparent external communication. Conclusion: PPEF could enable payers to formally solicit and utilize patient input to strengthen RD formulary decisions and enhance orphan drug access and RD patient outcomes.\",\"PeriodicalId\":432772,\"journal\":{\"name\":\"Future Rare Diseases\",\"volume\":\"112 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Rare Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/frd-2022-0016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Rare Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/frd-2022-0016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:在美国开发罕见病(RD)支付方-患者参与框架(PPEF),将患者偏好/输入纳入支付方处方决策。材料与方法:对药品价值评估、伦理决策、企业社会绩效等相关理论进行有针对性的文献综述,并结合美国24个支付方和患者利益相关者访谈结果构建PPEF。结果:已发表的文献显示,支付方很少使用患者偏好/投入,支付方的伦理处方决策与支付方的道德意图/行为/行动之间的潜在关系,以及他们的外部可信度和声誉。付款人/患者访谈确定了征求患者意见并将其纳入药物处方审查材料的正式和非正式方式。制定PPEF是为了吸引患者,评估并根据证据采取行动,并进行透明的外部沟通。结论:PPEF可以使支付方正式征求和利用患者的意见,以加强RD处方决策,提高孤儿药可及性和RD患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Payer–patient engagement framework to strengthen ethical formulary decision-making in rare disease arena in the USA
Aim: Develop a Payer–Patient Engagement Framework (PPEF) in rare disease (RD) to incorporate patient preferences/input into payer formulary decisions in the USA. Materials & methods: Targeted literature reviews related to drug value assessment, ethical decision-making and corporate social performance theories were conducted, and integrated with results from 24 payer and patient stakeholder interviews in the USA to construct PPEF. Results: Published literature revealed scant use of patient preferences/input by payers, and the potential relationship between payer's ethical formulary decisions and payer's moral intent/behavior/actions, and their external credibility and reputation. Payer/patient interviews identified formal and informal ways to solicit patient input and incorporate them in drug formulary review materials. PPEF was formulated to engage patients, assess, and act on evidence and perform transparent external communication. Conclusion: PPEF could enable payers to formally solicit and utilize patient input to strengthen RD formulary decisions and enhance orphan drug access and RD patient outcomes.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信